Yingjun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Yingjun Li has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Xumu Zhang
Department of Chemistry and Shenzhen Grubbs Institute Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis Southern University of Science and Technology Shenzhen China
11 shared publications - Deyin Guo
State Key Laboratory of Respiratory Disease National Clinical Research Center for Respiratory Disease Guangzhou Institute of Respiratory Health the First Affiliated Hospital of Guangzhou Medical University Guangzhou China
6 shared publications Qifan Zhou
Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, Shenzhen Grubbs Institute and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen 518000, China
6 shared publicationsYujian Yang
Department of Chemistry, College of Science, Academy for Advanced Interdisciplinary Studies, and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, Guangdong, 518000, China
6 shared publicationsTiefeng Xu
Centre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Guangzhou 518107, China
5 shared publicationsFeng Cong
Guangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou 510663, China
4 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Review of 2025 approved small-molecule drugs by China NMPA: A new milestone
- 17 October 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Open AccessReview of 2025 approved small-molecule drugs by China NMPA: A new milestone
- 26 February 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 174, 109690
Design, synthesis and pharmacological evaluation of phenylthiophene-2-carboxamide-based RSV fusion protein inhibitors
- 26 February 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 174, 109690
Design, synthesis and pharmacological evaluation of phenylthiophene-2-carboxamide-based RSV fusion protein inhibitors
- Open Access
- 2 December 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 728-745
Anti-influenza drugs targeting trimeric RNA polymerase complex: From development to clinics
- 2 December 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 728-745
Open AccessAnti-influenza drugs targeting trimeric RNA polymerase complex: From development to clinics
- Open Access
- 13 August 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (33) , 38175-38181
Development and Optimization of a Novel Synthetic Route for 2,4-Diamine-quinazoline Containing Ziresovir: A Drug Candidate for the Treatment of Respiratory Syncytial Virus (RSV) Infection
Ziresovir (AK0529) is a potent fusion (F) protein inhibitor featuring a quinazoline-2,4-diamine core and is currently a Phase III clinical drug candidate for the treatment of respiratory syncytial virus (RSV) infectious diseases. The existing synthetic routes to Ziresovir involve two consecutive nucleophilic substitutions on 2,4-dichloro-6-methylquinazoline with amines, which often result in undesired side products and require harsh conditions for the second chlorine substitution. In this study, we report the development and optimization of a streamlined, three-step synthesis of Ziresovir. The process begins with a copper-catalyzed ring closure reaction between 2-bromobenzoic acid and guanidine to form substituted quinazoline scaffolds. Subsequent chlorination with POCl3 produces intermediate 4-chloroquinazoline compound 19. Finally, nucleophilic substitution of compound 19 with 3-amino-3-oxetanylmethylamine yields the target molecule, Ziresovir. This chromatography-free process offers practical advantages, offering a viable pathway for the production of Ziresovir and other quinazoline analogs.
- 13 August 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (33) , 38175-38181
Open AccessDevelopment and Optimization of a Novel Synthetic Route for 2,4-Diamine-quinazoline Containing Ziresovir: A Drug Candidate for the Treatment of Respiratory Syncytial Virus (RSV) Infection
Ziresovir (AK0529) is a potent fusion (F) protein inhibitor featuring a quinazoline-2,4-diamine core and is currently a Phase III clinical drug candidate for the treatment of respiratory syncytial virus (RSV) infectious diseases. The existing synthetic routes to Ziresovir involve two consecutive nucleophilic substitutions on 2,4-dichloro-6-methylquinazoline with amines, which often result in undesired side products and require harsh conditions for the second chlorine substitution. In this study, we report the development and optimization of a streamlined, three-step synthesis of Ziresovir. The process begins with a copper-catalyzed ring closure reaction between 2-bromobenzoic acid and guanidine to form substituted quinazoline scaffolds. Subsequent chlorination with POCl3 produces intermediate 4-chloroquinazoline compound 19. Finally, nucleophilic substitution of compound 19 with 3-amino-3-oxetanylmethylamine yields the target molecule, Ziresovir. This chromatography-free process offers practical advantages, offering a viable pathway for the production of Ziresovir and other quinazoline analogs.
- Open Access
- 10 March 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (5) , 2498-2510
Anti-SARS-CoV-2 prodrug ATV006 has broad-spectrum antiviral activity against human and animal coronaviruses
- 10 March 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (5) , 2498-2510
Open AccessAnti-SARS-CoV-2 prodrug ATV006 has broad-spectrum antiviral activity against human and animal coronaviruses
- Open Access
- 9 December 2024
- Published by Georg Thieme Verlag KG in Pharmaceutical Fronts
- Vol. 06 (04) , e421-e429
Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity
Hypoxia-inducible factors (HIFs) play a key role in regulating cellular responses to low-oxygen conditions, particularly in promoting angiogenesis in tumor microenvironments. Aberrant HIF signaling enhances tumor growth and contributes to resistance against chemotherapy and radiotherapy. Targeting the HIF pathway has emerged as a promising strategy for cancer therapy. This study aimed to identify novel inhibitors of HIF signaling and evaluate their potential against the HIF–vascular endothelial growth factor (VEGF) axis for antiangiogenic therapy. In screening our in-house drug library using hypoxia response element dual-luciferase assay, HST3782, a novel 3-hydroxy-8-azabicyclo[3.2.1]octane-bridged compound, was identified as a promising HIF inhibitor, with IC50 of 1.028 μmol/L. In this work, the inhibitory effect of HST3782 on HIF signaling was confirmed in triple-negative breast cancer cells (SUM159) under hypoxic conditions (1% O2). Quantitative real-time polymerase chain reaction suggested the inhibitory effect of HST3782 on the expression of angiogenic genes, including VEGFa, VEGFR-1, BNIP3, and SERPINE1 in 786-O cells. Zebrafish model testing revealed that HST3782 inhibited intersegmental and subintestinal vessel development by up to 56% without marked toxicity. HST3782 was synthesized through a two-step 1,2,4 triazole cyclization reaction, followed by amide formation and ketone reduction steps. The last step of hydrogenation with sodium borohydride yielded a pair of endo-exo isomers. 2D-NOESY (Nuclear Overhauser effect spectroscopy) analysis confirmed that the compound's endo isomer (HST3782) had superior inhibitory effects relative to its exo form (8b). Given the above, HST3782 is a novel HIF inhibitor, with strong antiangiogenic effects and presents a valuable scaffold for future development of antiangiogenic drugs targeting the HIF–VEGF axis. Further studies are warranted to optimize HST3782's pharmacokinetics and therapeutic efficacy for antiangiogenic therapy in hypoxia-related malignancies. # These authors contributed equally to this work. Received: 04 April 2024 Accepted: 05 November 2024 Article published online: 09 December 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 9 December 2024
- Published by Georg Thieme Verlag KG in Pharmaceutical Fronts
- Vol. 06 (04) , e421-e429
Open AccessScreening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity
Hypoxia-inducible factors (HIFs) play a key role in regulating cellular responses to low-oxygen conditions, particularly in promoting angiogenesis in tumor microenvironments. Aberrant HIF signaling enhances tumor growth and contributes to resistance against chemotherapy and radiotherapy. Targeting the HIF pathway has emerged as a promising strategy for cancer therapy. This study aimed to identify novel inhibitors of HIF signaling and evaluate their potential against the HIF–vascular endothelial growth factor (VEGF) axis for antiangiogenic therapy. In screening our in-house drug library using hypoxia response element dual-luciferase assay, HST3782, a novel 3-hydroxy-8-azabicyclo[3.2.1]octane-bridged compound, was identified as a promising HIF inhibitor, with IC50 of 1.028 μmol/L. In this work, the inhibitory effect of HST3782 on HIF signaling was confirmed in triple-negative breast cancer cells (SUM159) under hypoxic conditions (1% O2). Quantitative real-time polymerase chain reaction suggested the inhibitory effect of HST3782 on the expression of angiogenic genes, including VEGFa, VEGFR-1, BNIP3, and SERPINE1 in 786-O cells. Zebrafish model testing revealed that HST3782 inhibited intersegmental and subintestinal vessel development by up to 56% without marked toxicity. HST3782 was synthesized through a two-step 1,2,4 triazole cyclization reaction, followed by amide formation and ketone reduction steps. The last step of hydrogenation with sodium borohydride yielded a pair of endo-exo isomers. 2D-NOESY (Nuclear Overhauser effect spectroscopy) analysis confirmed that the compound's endo isomer (HST3782) had superior inhibitory effects relative to its exo form (8b). Given the above, HST3782 is a novel HIF inhibitor, with strong antiangiogenic effects and presents a valuable scaffold for future development of antiangiogenic drugs targeting the HIF–VEGF axis. Further studies are warranted to optimize HST3782's pharmacokinetics and therapeutic efficacy for antiangiogenic therapy in hypoxia-related malignancies. # These authors contributed equally to this work. Received: 04 April 2024 Accepted: 05 November 2024 Article published online: 09 December 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 18 October 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 153, 107894
Identification of adenosine analogues as nsp14 N7‑methyltransferase inhibitors for treating coronaviruses infection
- 18 October 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 153, 107894
Identification of adenosine analogues as nsp14 N7‑methyltransferase inhibitors for treating coronaviruses infection
- 28 September 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116922
Synthesis and anti-influenza virus activity of substituted dibenzoxepine-based baloxavir derivatives
- 28 September 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116922
Synthesis and anti-influenza virus activity of substituted dibenzoxepine-based baloxavir derivatives
- 20 November 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (6) , 2188-2195
Optimized Kilogram-Scale Synthesis and Impurity Identification of SHEN26 (ATV014) for Treating COVID-19
- 20 November 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (6) , 2188-2195
Optimized Kilogram-Scale Synthesis and Impurity Identification of SHEN26 (ATV014) for Treating COVID-19